Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy

Abstract Introduction This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu®, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders to previous anti-vascular endothelial...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicolò Ribarich, Marco Battista, Lisa Checchin, Riccardo Sacconi, Francesco Bandello, Giuseppe Querques
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Ophthalmology and Therapy
Subjects:
Brolucizumab
Pachychoroid syndrome
Choroidal neovascularization
Online Access:https://doi.org/10.1007/s40123-025-01208-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40123-025-01208-w

Similar Items